June 02, 2025

New COVID Vaccine Approved for High-Risk Groups

After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.

Conexiant

May 30, 2025

HPV Vaccine After Surgery Reduces Virus Persistence

Post-surgical HPV vaccination was linked to significantly lower rates of HPV positivity in women with cervical lesions, suggesting a potential role in viral clearance and reduced persistence after treatment.

Conexiant

May 30, 2025

MASLD During Pregnancy Triples Preterm Birth Risk

Women with biopsy-confirmed MASLD faced triple the risk of preterm birth and higher emergency cesarean rates, even when controlling for obesity and family-related factors.

Conexiant

May 29, 2025

Gene-Based Hormone Match Improves IVF Birth Rates

A study found that matching FSH type to a woman's FSHR N680S gene variant significantly boosted IVF pregnancy and birth rates by up to 38%.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

Cardiogenic Shock in Women: Treatment Disparities Persist

New expert consensus statement reveals that women with cardiogenic shock face significant treatment disparities and outlines evidence-based recommendations for improving outcomes.

Conexiant

May 21, 2025

Medical Oddities: Fingernail Selfies Spot Anemia

Tea, tech, TikTok & toxins: surprising health twists hiding in phones, roads, and skin care.

Conexiant

May 21, 2025

Pregnancy Linked to Lower Long COVID Risk

New research analyzing over 72,000 pregnant COVID-19 patients reveals they face a significantly reduced risk of developing long-term symptoms compared to nonpregnant women, with key risk factors identified across both cohorts.

Conexiant

May 21, 2025

Most Molar Pregnancies Don’t Lead to GTN: Study 

A 40-year study of over 17,000 patients shows that most women whose hCG levels normalize within 56 days after a molar pregnancy are at very low risk for developing gestational trophoblastic neoplasia.

Conexiant